# University of Michigan: Early phase 1 study completed, 21 enrolled (Platelet Function and Reactivity Tests)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | University of Michigan |
| Sponsor type | Academic and hospital |
| Study | Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs |
| NCT ID | NCT06933056 |
| Phase | Early phase 1 |
| Status | completed |
| Conditions | Platelet Function and Reactivity Tests |
| Intervention types | drug |
| Target enrollment | 21 |
| Site countries | United States |
| Posted | 2025-04-18 |
| Planned start | 2025-09-02 |
| Event | Completed |
| Event date | 2026-10-19 |
| Last update posted | 2026-10-22 |

## Why this score
- Posted in the last two weeks.
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06933056). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.